Pull to refresh
Logo
Daily Brief
Following
Why Sign Up
Standard BioTools (formerly Fluidigm)

Standard BioTools (formerly Fluidigm)

Life Sciences Tools Company

Appears in 1 story

Stories

Precision proteomics companies race to commercialize blood-based disease detection

New Capabilities

Merged with SomaLogic, operates combined proteomics platform

Alamar Biosciences raised $191 million in its initial public offering on April 17, 2026 — nearly double the $100 million it originally planned — after investor demand exceeded available shares by more than tenfold. The Fremont, California company develops technology that detects proteins in blood at concentrations so low that conventional tests miss them entirely, potentially catching diseases years earlier than current methods allow. The company reported $74 million in revenue for fiscal year 2025, giving public investors a baseline for tracking commercial growth against the IPO's lofty expectations.

Updated 2 hours ago